Educational Session : Market Outlook – IPOs Ascendant and Watching M&A Valuations

okt 18, 2018: 4 p.m. - 4:55 p.m.
California West

Despite heightened political discussion of the value of marketed medicines, the biopharma investor community continues to increase its support. As the industry has gained traction on new drug approvals through 2018, the financial dollars have followed with record public and private offerings. The attractive IPO market has however resulted in fewer M&A deals than prior years, with high pre-money IPO valuations for later-stage companies making it less enticing for them to accept early-exit offers. This has led to an M&A shift to focus on early-stage companies. The session will examine the current deals and market trends while highlighting the path forward.

Moderated by: Gregory Wade, PhD Managing Director,�Healthcare Investment Banking at BTIG.


Rajeev Dadoo

Anna French

Ken Haas

Matt McAviney

Gregory Wade
Managing Director, He...

Jimmy Z. Zhang
Venture Partner